SEngine Precision Medicine raises $5.1m in a Series A investment round to further develop its 3D tumor organoid diagnostic and drug discovery platform.
Researchers develop organ-on-an-electronic-chip platform to explore the electrophysiology of iPSC-derived cardiomyocytes and understand how the heart communicates.
Prellis advances its goal of using 3D holographic printing to create organoids for research and development – recently closing a $10.5m investment round to further develop its technology, which accelerates drug screening, says CEO.
Using its proprietary bioprocessing technology, Cellesce is scaling the production of breast organoids for drug discovery research – with plans to expand into other areas of unmet medical need, says CEO.
